The DOI matches its Crossref record.
The Contribution of P‐glycoprotein to Pharmacokinetic Drug‐Drug Interactions
Abstract
P‐glycoprotein (PGP) is well known because of its contribution to multiple‐drug resistance during anticancer treatment. More recent work indicates that PGP mediates the transcellular transport of many drugs in addition to anticancer compounds. Because of this reason, its potential role in clinically significant drug‐drug interactions has just begun to be realized. This article provides an overview of published in vitro, in situ, and in vivo drug‐drug interaction results that are related to PGP transport so that the awareness of the scientific community can be heightened. In addition, several recommendations are made to take full advantage of the recently published data.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Caco-2 cell permeability assays to measure drug absorption
van Breemen, R. B., & Li, Y. (2005) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.1.2.175 · Cited by 602
Molecular Basis of Ethnic Differences in Drug Disposition and Response
Xie, H.-G., Kim, R. B., Wood, A. J., & Stein, C. M. (2001) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.41.1.815 · Cited by 600
Impact of Drug Transporter Studies on Drug Discovery and Development
Mizuno, N., Niwa, T., Yotsumoto, Y., & Sugiyama, Y. (2003) · Pharmacological Reviews · doi:10.1124/pr.55.3.1 · Cited by 490
Inhibition of the Multidrug Resistance P-Glycoprotein: Time for a Change of Strategy?
Callaghan, R., Luk, F., & Bebawy, M. (2014) · Drug Metabolism and Disposition · doi:10.1124/dmd.113.056176 · Cited by 453
Risk for Myopathy With Statin Therapy in High-Risk Patients
Ballantyne, C. M., Corsini, A., Davidson, M. H., Holdaas, H., Jacobson, T. A., Leitersdorf, E., März, W., Reckless, J. P. D., & Stein, E. A. (2003) · Archives of Internal Medicine · doi:10.1001/archinte.163.5.553 · Cited by 453
Herbal Modulation of P‐Glycoprotein
Zhou, S., Lim, L. Y., & Chowbay, B. (2004) · Drug Metabolism Reviews · doi:10.1081/dmr-120028427 · Cited by 375
Herb–drug interactions: Review and assessment of report reliability
Fugh‐Berman, A., & Ernst, E. (2001) · British Journal of Clinical Pharmacology · doi:10.1046/j.0306-5251.2001.01469.x · Cited by 364
Zhang, S., & Morris, M. E. (2003) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.044412 · Cited by 309
The Influence of Age and Sex on the Clearance of Cytochrome P450 3A Substrates
Cotreau, M. M., von Moltke, L. L., & Greenblatt, D. J. (2005) · Clinical Pharmacokinetics · doi:10.2165/00003088-200544010-00002 · Cited by 292
Inhibition of P-Glycoprotein by Newer Antidepressants
Weiss, J., Dormann, S.-M. G., Martin-Facklam, M., Kerpen, C. J., Ketabi-Kiyanvash, N., & Haefeli, W. E. (2003) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.046532 · Cited by 292
Safety and Efficacy of Statins in Asians
Liao, J. K. (2007) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2006.08.051 · Cited by 267
Remimazolam: non-clinical and clinical profile of a new sedative/anesthetic agent
Kilpatrick, G. J. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.690875 · Cited by 262
MDR- and CYP3A4-mediated drug–herbal interactions
Pal, D., & Mitra, A. K. (2006) · Life Sciences · doi:10.1016/j.lfs.2005.12.010 · Cited by 254
Classification Analysis of P-Glycoprotein Substrate Specificity
Didziapetris, R., Japertas, P., Avdeef, A., & Petrauskas, A. (2003) · Journal of Drug Targeting · doi:10.1080/10611860310001648248 · Cited by 253
Pharmacokinetic Interactions of Drugs with St John’s Wort
Zhou, S., Chan, E., Pan, S.-Q., Huang, M., & Lee, E. J. D. (2004) · Journal of Psychopharmacology · doi:10.1177/0269881104042632 · Cited by 253
A Comparison of Pharmacokinetics between Humans and Monkeys
Akabane, T., Tabata, K., Kadono, K., Sakuda, S., Terashita, S., & Teramura, T. (2010) · Drug Metabolism and Disposition · doi:10.1124/dmd.109.028829 · Cited by 97
Clinically Significant Drug Interactions with Atypical Antipsychotics
Kennedy, W. K., Jann, M. W., & Kutscher, E. C. (2013) · CNS Drugs · doi:10.1007/s40263-013-0114-6 · Cited by 95
“The P-glycoprotein structure and its molecular efflux action have been described with two separate binding sites for either lipophilic or hydrophilic molecules [20].”
BackgroundThe safety of HMG-CoA reductase inhibitors in special populations at high cardiovascular risk
Corsini, A. (2003) · Cardiovascular Drugs and Therapy · doi:10.1023/a:1026132412074 · Cited by 82
Metadata
- Authors
- Yu, D. K.
- Venue
- The Journal of Clinical Pharmacology
- Publisher
- Wiley
- Published
- 1999-12
- Volume
- 39
- Issue
- 12
- Pages
- 1203-1211
- ISSN
- 0021-9754 (ISSN-L)
- 0091-2700
- 1552-4604
- OpenAlex
- W2126310184
- Cited by
- 199
- References
- 0
- FWCI
- 5.66
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.